<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the clinical implications of soluble CD44 (sCD44) levels in hematologic <z:hpo ids='HP_0002664'>neoplasias</z:hpo>, we developed an enzyme-linked immunosorbent assay for sCD44 using two monoclonal antibodies to the standard 90 kDa form, and assessed the serum concentration of sCD44 in <z:mpath ids='MPATH_458'>normal</z:mpath> healthy volunteers, patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and those with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>Compared to that in <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (n=51; 145 </plain></SENT>
<SENT sid="2" pm="."><plain>1 24.6 ng/ml), the serum sCD44 level was significantly elevated in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n=18; 331.9 99.0 ng/ml, P=0.0001), <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> (ALL; n=16; 551.3 427.8 ng/ml, P=0.0001) and <z:mp ids='MP_0005481'>CML</z:mp> (n=18; 262.0 97.5 ng/ml, P=0.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>The sCD44 level was slightly elevated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n=43; 173.8 54.9 ng/ml, P=0.0071) </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, serum sCD44 concentrations decreased significantly in response to treatment and reached nearly <z:mpath ids='MPATH_458'>normal</z:mpath> levels after complete remission (P=0.0005 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and P=0.0032 in ALL) </plain></SENT>
<SENT sid="5" pm="."><plain>The sCD44 levels in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> increased after they developed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, whereas no significant difference in sCD44 levels was observed between the <z:hpo ids='HP_0011010'>chronic</z:hpo> and the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phases</z:e> in patients with <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Our results indicate that serum sCD44 levels may be a useful marker for monitoring response to treatment and disease progression, especially in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>